Female Genital Schistosomiasis (FGS): Sub-Saharan Africa’s Secret Scourge of Girls and Women

PLOS NTDs editor-in-chief Peter Hotez highlights the subject of Female Genital Schistosomiasis in Africa that continues to affect women there heavily, yet receives disproportionally little attention.

Last month, together with Prof. Paul Brindley I wrote about new advances in the study of schistosomiasis caused by Schistosoma haematobium, best known as the cause of urinary tract schistosomiasis and bladder cancer in Africa.  Our article highlighted new animal models, the development of in vitro systems, and the recent completion of the S. haematobium genome leading to recent insights into parasite-induced carcinogenesis.  Compared to the other schistosomes S. haematobium has been relatively neglected by the scientific community in terms of number of citations in the scientific literature, especially since it is the world’s most common schistosome responsible for approximately two-thirds (actually 67%) of the schistosomiasis cases in sub-Saharan Africa where more than 90% of the disease burden occurs.

Mbabazi PS, Andan O, Fitzgerald DW, Chitsulo L, Engels D, et al. (2011) Examining the Relationship between Urogenital Schistosomiasis and HIV Infection. PLoS Negl Trop Dis 5(12): e1396. doi:10.1371/journal.pntd.0001396

Mbabazi PS, Andan O, Fitzgerald DW, Chitsulo L, Engels D, et al. (2011) Examining the Relationship between Urogenital Schistosomiasis and HIV Infection. PLoS Negl Trop Dis 5(12): e1396. doi:10.1371/journal.pntd.0001396

In this and several other articles published in PLOS Neglected Tropical Diseases since 2009 we have tried to consistently emphasize the disproportionate impact of S. haematobium infection on girls and women.  Schistosome eggs embolize to the  uterus, cervix, and lower genital tract of girls and women to form fibrotic nodules known as “sandy patches” that result in a condition known as female genital schistosomiasis (FGS), which is associated with bleeding and pain (especially during sexual intercourse), as well as social stigma and depression.  I have also written about FGS in the lay press.

Some preliminary calculations provide cause for concern about the high prevalence of FGS.  Using the World Health Organization’s conservative estimate of 235 million cases of schistosomiasis or revised estimates from Prof. Charles King of 586-659 million people living with some form of schistosomiasis, and the fact that more than 90% of the global cases occur in sub-Saharan Africa, we can determine that between 200 million and 600 million people suffer from schistosomiasis in sub-Saharan Africa.  Assuming an equal sex distribution these numbers equate to approximately 100-300 million girls and women affected by schistosomiasis.  Using the 67% number for the percentage of cases caused by S. haematobium, there are approximately 67-200 million cases of S. haematobium infection among girls and women.  Further estimates that between 33%% and 75% of girls and women with S. haematobium infection also suffer from FGS in their lower genital tract would indicate that between 20 million and 150 million girls are affected, possibly making FGS one of the most common gynecologic conditions in sub-Saharan Africa where it is a horrific and widespread cause of bleeding, pain, depression, and stigma.
Continue reading »

Category: General, Neglected Diseases | 3 Comments

MSF Scientific Day 2013

Does blogging help patients cope with the lengthy and toxic treatment for multidrug resistant tuberculosis? Do humanitarian responses to crises fail to take sufficient account of the plight of elderly people? Is giving money more effective than giving food supplements to tackle child malnutrition? And will global health expert and Ted Talks alumnus Hans Rosling repeat his sword swallowing routine? These are just a few of the questions that will be answered at the 2013 Médecins Sans Frontières (MSF) Scientific day, screened online live all day from the Royal Society of Medicine, London, UK, on Friday, May 10th.

logo_jpeg_newsite

The agenda is packed with presentations that reflect the diversity of MSF programmes and patients – from examining the experience of bloggers in the MSF TB&Me blog to the use of a cholera vaccine during an outbreak in Guinea to treating tuberculosis in the extremely insecure setting of Somalia. There are innovative tools and approaches, such as seasonal chemoprevention for malaria and large-scale treatment with chelation for thousands of children with severe lead poisoning in northern Nigeria.
Continue reading »

Category: Conference news, General, MSF | Tagged , , , | 1 Comment

This Week in PLOS NTDs and PLOS Pathogens: Tracing the Justinianic Plague; Prudence in Diagnosing Rabies; the Functions of PolyP; Thermal Treatment for Leishmaniasis; and More

ppat.1003331

Caffaro CE, Koshy AA, Liu L, Zeiner GM, Hirschberg CB, et al. (2013) A Nucleotide Sugar Transporter Involved in Glycosylation of the Toxoplasma Tissue Cyst Wall Is Required for Efficient Persistence of Bradyzoites. PLoS Pathog 9(5): e1003331. doi:10.1371/journal.ppat.1003331

The following new articles are publishing in PLOS NTDs this week:

Chronic American cutaneous leishmaniasis is expensive and difficult to treat using conventional techniques that have major adverse side effects. In this paper Dr. Braulio Valencia and colleagues outline a low-cost heat treatment device that produces a therapeutic and stable thermal reaction ranging from 50-54°C. Patients treated during the pilot program experienced cure rates near the standard antimonial treatment.

In this systematic review article Dr. Philippe Carrara and colleagues examine the cases of sixty travelers and expatriates infected with rabies whose origins are from non-endemic nations. Their findings suggest that taking saliva samples and skin biopsies from those visiting rabies-enzootic countries is a prudent precaution, as a diagnosis of viral infection is not always clearly evident.

Exosomes are considered an important route of communication among cells, and depending on various factors these can have distinct effects on recipient cells. In this paper Drs. Kasra Hassani and Martin Olivier describe the effect of leishmania infection and LPS stimulation on protein-content and stimulatory properties of macrophage exosomes. Overall, these results give a deeper understanding of exosome biology and its role in the host-parasite interactions of leishmania.

The following new articles are publishing in PLOS Pathogens this week:

Of the three most devastating pandemics in human history only two have been linked to Yersinia pestis, the bacterium responsible for the plague known as the Black Death. However the first pandemic (the Justinianic Plague), which began in the 6th century is still a matter of controversy. Dr. Harbeck and colleagues detect Y. pestis DNA in samples obtained from multiple 6th century skeletons from Germany confirming that Justinianic Plague affected local populations there.

Polyphosphate (polyP) is a linear polymer found in bacteria, protists and mammalian cells of a few to many hundreds of phosphate (Pi) residues linked by high-energy phosphoanhydride bonds. In this Pearl, Drs. Moreno and Docampo discuss the functions of PolyP, the enzymes involved in PolyP metabolism, and their current role in pathogenesis.

It is widely accepted that the tissue cyst perimeter of Toxoplasma gondii is highly and specifically decorated with glycan modifications; however, the role of these modifications in the establishment and persistence of chronic infection has not been investigated. Dr. Caffaro and colleagues demonstrate for the first time the critical role of parasite glycoconjugates in the persistence of Toxoplasma tissue cysts.

Category: General | Leave a comment

Spotlight from the CUGH Conference 2013: Innovative Technologies

I recently attended the Consortium of Universities for Global Health (CUGH) conference in Washington DC from March 13-16, 2013. I found the talks on Innovative Technologies most interesting, in part because technologies have a large impact on the everyday lives of people in developing countries. One technology that Dr. Sasha Kramer, an ecologist from Stanford University, presented was the design and implementation of a new type of compost toilet for use in Haiti, funded by grants and donations. Her idea aims to improve basic sanitation, reduce the risk of diseases like cholera, and create jobs for unemployed Haitians.

Kramer is the executive director and co-founder of the not-for-profit organization Sustainable Organic Integrated Livelihoods (SOIL), which has built more than 50 public composting toilet facilities in Haiti since 2006.  Eighty percent of the population in Haiti does not have access to basic sanitation and existing toilets are not well designed, with human waste flushing straight into rivers or groundwater. In this way the water supply is easily contaminated, and waterborne diseases like cholera are at epidemic levels in Haiti. From the SOIL website: “As of March 4, 2013, cholera has killed 8,057 Haitians and infected nearly 650,000 more. Despite some claims of progress, the epidemic, which was introduced by United Nations troops, has been significantly worse in 2013 than during the same period the year before.”
Continue reading »

Category: Conference news, General | Tagged , , | Leave a comment

PLOS Pathogens heads back to Brazil this month for Keystone Symposium on the Innate Immune Response in the Pathogenesis of Infectious Disease!

We are pleased to announce that PLOS Pathogens will be attending the Keystone Symposium on the Innate Immune Response in the Pathogenesis of Infectious Disease at Universidade Ferederal de Ouro Preto (UFOP) in lovely, historical Ouro Preto, MG, Brazil from May 10 -15.

Image credit: Cid Costa Neto

Igreja São Francisco de Paula, Ouro Preto. Image Credit: Cid Costa Neto, Wikimedia Commons

Ricardo Gazzineli, one of PLOS Pathogen’s Associate Editors in the parasitology section, is one of the co-organizers of this meeting.  The meeting will focus on, “the interface of the innate immune system and the microbial pathogens and the role that it plays in protective versus deleterious immune responses and, thereby, of disease outcome.” Scientists from a number of fields will be represented at this symposium, including but not limited to: cell biology, tropical medicine, biochemistry, parasitology, and biotechnology. To learn even more about the symposium, view a video here.

We are happy to be returning to Brazil for this symposium and are very much looking forward to connecting with members of our Editorial Board who will be presenting at the conference as well as meeting numerous attendees and sharing information about the journal. If you are attending this meeting and would like to meet PLOS Pathogens staff, contact us at plospathogens@plos.org or via twitter @PLOSPathogens.

During the symposium, Cory Mann and I (Gina Alvino) will be easy to spot in our PLOS t-shirts and/or buttons, so please do not hesitate to come over and speak with us about the journal! We will be well-supplied with a plethora of informational materials about PLOS Pathogens (in both English and Portuguese) and general PLOS information, as well. As with all other conferences PLOS attends, we will have with us an array of PLOS memorabilia including magnets, buttons and of course, pens!

Throughout the symposium we will be sharing highlights on social media sites such as Twitter and Facebook so that our friends and followers can stay updated. The twitter hashtag for this symposium is #KSimmunity.

Category: General | Tagged , , | Leave a comment

Turning the World Upside Down

Isobel Braithwaite shares her thoughts on the recent launch event of the Turning the World Upside Down online platform.

A couple of weeks back, I attended the launch event of the new Turning the World Upside Down (TTWUD) website, which was hosted by Nigel Crisp, ex-chief executive of the UK’s National Health Service and author of a great book of the same name, and organised by Medsin’s director, Jonny Meldrum.  It was a very thought-provoking event, and the site itself is already full of various interesting and unusual case studies from across the world.

TTWUDNear the start of the launch, Paul Farmer (a physician and medical anthropologist who is also the Chair of Harvard’s Department of Global Health, a founding director of the international non-profit Partners In Health, and an all-round inspirational person) made the simple point that global health is basically all about equity.  It’s an often made point, but it can’t be repeated enough.  It’s why I care about global health, and why I first became involved in the student global health network Medsin, focusing mainly on the topic of climate change and health.  Health equity is also under siege right on our doorstep here in the UK, with the current erosion of various safety nets and what sometimes looks rather like wholesale abandonment of the goal of health equity.

Improving global health is also about using and sharing knowledge on what works and to that end, TTWUD seeks to facilitate ‘co-development’ – as Nigel Crisp eloquently puts it – through mutual teaching and learning, by global health professionals and stakeholders from high, low and middle income countries alike.
Continue reading »

Category: Students | Tagged , , , , , , | Leave a comment

European Court is on the Wrong Side on Patient Safety

Síle Lane from Sense About Science discusses the recent European Court injunction on clinical trial data.

AllTrials logo for website (2)The European General Court has issued an injunction to prevent the European medicines regulator from releasing information from clinical trials conducted by AbbVie and InterMune at the request of the two companies. While yesterday’s ruling pertains to two particular cases it has ramifications for all.

The Court’s decision puts the European Medicines Agency into conflict with its own policy, announced in 2012, to proactively release data from clinical trials supporting the authorisation of medicines being used by patients all over Europe. The Clinical Study Reports that EMA has made available since last year were one of the few ways that researchers could access otherwise withheld material. Their release was instrumental in spotting serious flaws in the evidence for Roche’s drug Tamiflu, for example, which the UK government alone spent £500m on in one year.

More importantly the Court’s decision at the request of AbbVie and InterMune puts it into conflict with the interests of patients. When GSK joined the AllTrials campaign and promised to publish all the CSRs available since its formation as a company they said that they owe this to the patients who have taken part in their trials. Two hundred other organisations including more than 100 patient groups and 50,000 people have signed up to the campaign calling on regulators worldwide to do everything they can to secure registration and publication of the results of clinical trials.

So we’re on the brink. Patients and researchers all over the world have started pushing for historic change. GSK has shown that it’s not beyond the reach of pharma companies to agree to that change. The EMA has tried going some way to delivering on that change.

But, EMA now has to decide if the European Court’s ruling will divert them from their policy to publish trial information. We will be sending the EMA the AllTrials petition. We will be asking them to continue their fight for transparency and showing them that tens of thousands of people are asking why they don’t have access to the evidence behind the medicines they use, prescribe and research. Will you help us today at www.alltrials.net? Please, ask your colleagues and friends to add their voices and ask them to forward this to others when they have.

The European Court has indicated that it is on the wrong side of history. The EMA now has to show that arguments in favour of secrecy no longer hold.

Síle Lane is director of campaigns at Sense About Science

 

Category: Access, General | Tagged , , , , | 8 Comments

Q&A with Pamela Collins – lead author of new series in PLOS Medicine on integrating mental health

2066_Columbia_Collins_20070711In the latest installment of the Speaking of Medicine series of Q&A blog posts, we hear from Pamela Collins, the corresponding author of a series of Policy Forum articles in PLOS Medicine that provides a global perspective on integrating mental health.  Pamela Collins M.D., M.P.H., is the Director of the Office for Research on Disparities and Global Mental Health at the National Institute of Mental Health (NIMH). I asked her about some of the topics discussed in the new series, which will be published in PLOS Medicine weekly for the  next five weeks, starting with the publication today of a Policy Forum article discussing integration in research, policy, and practice.

1. Why is the integration of mental health care so important?

Integration of mental health care is important on several levels. First, there is a need to integrate mental health concerns into the broader discussions in global public health because of the tremendous disability and suffering that mental disorders cause around the world. Mental disorders are global problems which, untreated, result in increased morbidity and mortality, as well as increased health system and societal costs.  Second, we know that mental disorders co-occur with many other medical conditions, including cardiovascular disease, diabetes, and HIV-related disease.  Depression is a good example. When depression co-occurs with these conditions, the risk of poor outcomes, including death, increases.  Third, integration of mental health interventions into other areas of routine care (e.g. primary care or maternal health care) has the potential for improving access to needed services, enabling health care providers to deliver holistic care.  Establishing access to evidence-based, effective care for depression in settings where women receive routine health services may increase the likelihood that women with depression receive the care they need.

2. What were your main motivations for initiating the series?

NIMH and its partners completed the priority setting initiative, the Grand Challenges in Global Mental Health, in 2011. One of the Grand Challenges identified by the group of international stakeholders was to “redesign health systems to integrate mental, neurological, and substance use (MNS) disorders with other chronic disease care, and create parity between mental and physical illness in investment to research, training, treatment and prevention.”  Notably, meeting this challenge requires the cooperation of stakeholders within and outside of the mental health arena.  It is timely, too.  Much of the global health community is now focused on how to leverage resources efficiently in order to achieve the best health outcomes for populations in need. Integrating mental health services that build on existing platforms may be one way to introduce efficiency.

3. How did you get interested in this area of research?

My past research focused on the intersection of mental health care and HIV-related care in high-, middle-, and low-income country settings.  I entered this arena of integration while first working to reduce the risk of HIV infection among women with schizophrenia, bipolar disorder, and depression in New York City in the 1990s, and I subsequently began to work with providers in South Africa and Rwanda around similar issues.  People with severe mental illnesses have a much higher prevalence HIV infection in the United States. Yet, this is not a population that we usually hear about in public health efforts to prevent HIV and care for people with HIV.  But the risk for HIV infection is not solely a high-income country phenomenon.  Studies from sub-Saharan Africa also show a high prevalence of HIV infection among people hospitalized in psychiatric facilities. This population also has higher rates of mortality and earlier mortality from non-communicable diseases.  These findings point to the possibility of integrated care as a means of insuring that people with mental illnesses gain access to the prevention and care they need for other health conditions.  At the same time people who develop a mental illness while being treated for other health conditions need access to services where the symptoms of mental illness will be recognized and treated appropriately.

4. What are the main barriers to moving this field forward?

One critical barrier is the inequity in human resources for health care around the world. There is a dearth of mental health care providers in many parts of the world. The 2011 WHO Mental Health Atlas tells us that nearly half of the world’s population lives in a setting with one psychiatrist or less serving 200,000 people. But, barriers also provide opportunities.  The mental health community has long experimented with using non-specialists to deliver mental health services including community health workers, nurses, or primary care doctors. We now have a growing number of rigorous studies that provide evidence that effective mental health interventions can be delivered by non-specialists in settings where the specialist workforce is simply insufficient.

5. What further research is needed in this area?

Given that the resources allocated for mental health care are limited in many settings, we need to understand the best methods of equipping available health care providers to deliver evidence-based mental health services, in tandem with interventions for other disorders, in a variety of health system environments.  We have tools, through the WHO Mental Health Gap Action Programme, to assist with screening for some MNS disorders, but we need more understanding of how disease processes interact to affect the course of illness.  As we will see in the concluding paper in the series, Vikram Patel and colleagues argue that at  the systems level, we have more to learn about how and where to integrate services for people with different kinds of mental illnesses, such as chronic psychosis, dementia, or childhood mental disorders.  Furthermore, most of the studies that provide the evidence base for integrating mental health services into other delivery platforms have been carried out in high-income countries, so we need more data from settings with fewer resources that show how best to provide these services. Last year NIMH published a funding opportunity announcement called “Grand Challenges in Global Mental Health: Integrating Mental Health into Chronic Disease Care Provision in Low- and Middle-Income Countries.”  We hope the studies to be funded through this initiative will answer some of these questions.


Category: Mental Health | 1 Comment

This Week in PLOS Medicine: Global Access to Health Information, Integrating Mental Health, Upper GI Bleeds, & Cinacalcet

Image Credit: Flickr Moving Mountains Trust

Image Credit: Flickr Moving Mountains Trust

This week PLOS Medicine offers a global perspective on access to health information and integrating mental health. New research articles on mortality after upper GI bleeding and cinacalcet for chronic kidney disease are also featured.

In April’s editorial, the PLOS Medicine Editors reflect on the critical need for access to high quality health information across the globe and a recent analysis suggesting that governments have a legal responsibility to ensure access to health information for their citizens and health workers.

In the first article of a five-part weekly series providing a global perspective on integrating mental health, Pamela Collins and colleagues set the scene for why mental health care should be combined with priority programs on maternal and child health, non-communicable diseases, and HIV, and how this might be done. Forthcoming papers in the series will examine the specific instances of integrating mental health with maternal health, HIV, and non-communicable disease care, and a final paper will address cross-cutting issues.

Colin Crooks and colleagues examine patient outcomes in the 5 years after a non-variceal upper gastrointestinal bleed and found an increased risk of all causes of death, over half of which were due to non-gastrointestinal causes, particularly malignant tumors and cardiovascular disease.

Giovanni Strippoli and colleagues report findings of a systematic review and meta-analysis examining the benefits and harms of calcimimetic therapy in adults with chronic kidney disease (CKD). The routine use of cinacalcet therapy in people with CKD does not appear warranted; benefits may be limited to preventing parathyroidectomy in the small number of patients for whom surgery is contraindicated.

Remember you can comment on, annotate and rate any PLOS Medicine article and see the views, citations and other indications of impact of an article on that articles metrics tab.

Category: General | Tagged , , , , , , , | Leave a comment

This Week in PLOS NTDs and Pathogens: Advancing Neurocysticercosis Research; Ivermectin vs. Onchocerciasis; Rhoptries Revealed; and HCV-Induced Liver Disease

Figure 3. Malhotra S, Yen JY, Honko AN, Garamszegi S, Caballero IS, et al. (2013) Transcriptional Profiling of the Circulating Immune Response to Lassa Virus in an Aerosol Model of Exposure. PLoS Negl Trop Dis 7(4): e2171. doi:10.1371/journal.pntd.0002171


Malhotra S, Yen JY, Honko AN, Garamszegi S, Caballero IS, et al. (2013) Transcriptional Profiling of the Circulating Immune Response to Lassa Virus in an Aerosol Model of Exposure. PLoS Negl Trop Dis 7(4): e2171. doi:10.1371/journal.pntd.0002171

The following new articles are publishing in PLOS NTDs this week:

Neurocysticercosis (NCC) is the most common cause of adult acquired epilepsy worldwide and one the most frequent parasitic infections associated with chronic morbidity encountered in the United States, but study of the disease remains underfunded. Here Dr. Theodore Nash and colleagues discuss the importance of NCC as a preventable and treatable infection, as well as advancements, goals, reasons for lack of material support and a roadmap for advancement.

Studies in Mali, Nigeria and Senegal have shown contradictory results concerning the efficacy of long-term ivermectin distribution for onchocerciasis elimination. Dr.

Hugo Turner and colleagues explore how assumptions regarding aspects of treatment effects can affect temporal projections of infection load and prevalence in highly endemic African savannah settings.

Despite the significant public health issues and potential biodefense risks posed by the Lassa virus (LASV) little is known of the human immune response to this hemorrhagic fever. Dr. Shikha Malhotra and colleagues outline here an unbiased genomics approach to map the temporal host response in the peripheral blood mononuclear cells of non-human primates exposed to LASV. Their results provide a picture of the host’s circulating immune response to LASV exposure and demonstrate that gene expression patterns correlate with specific stages of disease progression.

The following new articles are publishing in PLOS Pathogens this week:

As with many intracellular infectious agents, the protozoan Toxoplasma gondii has a quiver of effectors that it uses to co-opt host cell functions including several from a paralogous family of protein kinases and pseudokinases that are injected into the host cell from the apical secretory organelles known as rhoptries (ROPs). In this Pearl, Dr. John Boothroyd presents how these ROPs were found and the current state of knowledge about their function.

Hepatic inflammation during chronic HCV infection is considered to be the primary catalyst for progressive liver disease and development of liver cancer but the underlying molecular mechanisms are not well understood. The results from Dr. Amina Negashand and colleagues identify HCV-induced IL-1b production by hepatic macrophages as a critical and central process that promotes liver inflammation and disease.

Emerging evidence suggests that the p65 family of guanylate-binding proteins (GBPs), which is upregulated by interferon gamma, play an important role in host defense against intracellular pathogens. Dr. Elizabeth Selleck and colleagues provide findings that demonstrate that Gbp1 plays an important role in the IFN-c-dependent, cell-autonomous control of toxoplasmosis and predict a broader role for this protein in host defense.

Category: General, Neglected Diseases | Leave a comment